Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel
- PMID: 21359971
- DOI: 10.1007/s00702-011-0614-9
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel
Abstract
Levodopa/carbidopa (LD/CD) application elevates total plasma homocysteine (thcys). We determined thcys-, LD- and 3-O-methyldopa (3-OMD) concentrations in 28 patients with Parkinson's disease (PD) on a LD/CD duodenal gel treatment. We found a distinct thcys increase (29.52 ± 28.98 μmol/l [median ± SD]) above the 15 μmol/l threshold and a significant (R = 0.7) correlation between LD and 3-OMD. thcys ascent was observed in relation with the onset of atherosclerosis, non-motor symptoms and polyneuropathy in PD patients in the long term.
Similar articles
-
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.AAPS J. 2013 Apr;15(2):316-23. doi: 10.1208/s12248-012-9439-1. Epub 2012 Dec 11. AAPS J. 2013. PMID: 23229334 Free PMC article.
-
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.Mov Disord. 2017 Apr;32(4):624-625. doi: 10.1002/mds.26903. Epub 2017 Jan 24. Mov Disord. 2017. PMID: 28116835 No abstract available.
-
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2. CNS Drugs. 2015. PMID: 25895021 Free PMC article. Clinical Trial.
-
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.Expert Opin Drug Saf. 2015 May;14(5):761-7. doi: 10.1517/14740338.2015.1015986. Epub 2015 Feb 19. Expert Opin Drug Saf. 2015. PMID: 25697185 Review.
-
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].Neurologia. 2005 May;20(4):180-8. Neurologia. 2005. PMID: 15891947 Review. Spanish.
Cited by
-
Catechol-O-methyltransferase inhibitors in Parkinson's disease.Drugs. 2015 Feb;75(2):157-74. doi: 10.1007/s40265-014-0343-0. Drugs. 2015. PMID: 25559423 Review.
-
Malnutritional neuropathy under intestinal levodopa infusion.J Neural Transm (Vienna). 2012 Mar;119(3):369-72. doi: 10.1007/s00702-011-0689-3. Epub 2011 Jul 24. J Neural Transm (Vienna). 2012. PMID: 21786115
-
Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.J Neural Transm (Vienna). 2014 Oct;121(10):1269-72. doi: 10.1007/s00702-014-1204-4. Epub 2014 Apr 8. J Neural Transm (Vienna). 2014. PMID: 24710647
-
Oxidative stress in genetic mouse models of Parkinson's disease.Oxid Med Cell Longev. 2012;2012:624925. doi: 10.1155/2012/624925. Epub 2012 Jul 8. Oxid Med Cell Longev. 2012. PMID: 22829959 Free PMC article. Review.
-
Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Front Neurol. 2023 May 25;14:1174698. doi: 10.3389/fneur.2023.1174698. eCollection 2023. Front Neurol. 2023. PMID: 37305739 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials